I study the impact of respiratory virus infections in children and adults, with a special interest in patients at high risk for severe disease. I have studied the diagnosis, epidemiology, and prevention of respiratory diseases using novel diagnostic tests, vaccines, antivirals, and other therapeutics, and evaluated respiratory diseases in diverse populations, including neonates, pregnant women, immunocompromised children, and communities in the USA and developing countries. I have worked to improve prevention of viral diseases around the world. My recent work with the Seattle Flu Study (SFS) and Public Health WA and King County has resulted in landmark studies of SARS-CoV-2 in the community. We have conducted large-scale respiratory virus surveillance using innovative online recruiting and self-swabbing, resulting in identification of early SARS-CoV-2 community spread. SFS has pioneered innovative methods of diagnosis and study design in populations including households, homeless shelters and healthcare workers. I evaluate novel approaches to the diagnosis and treatment of respiratory viruses and vaccination in immunocompromised hosts with my colleagues at Fred Hutchinson Cancer Center, including Michael Boeckh, MD, and Alpana Waghmare, MD and Chikara Ogimi, MD. My long-standing partnership with Eileen Klein, MD, MPH, at Seattle Children’s Hospital has enabled research on respiratory and enteric viruses as part of the New Vaccine Surveillance Network in outpatient clinics, Emergency Department, and inpatient settings over the past 12 years. I have also studied new vaccines, vaccine uptake and acceptance in multiple settings, including hospitalized children, with Danielle Zerr, MD, MPH, and Annika Hofstetter, MS, MD, PhD.